A Study of Vancomycin and Daptomycin Minimum Inhibitory Concentration in Clinical Isolates of Staphylococcus Aureus At A Tertiary Care Hospital of Gujarat
DOI:
https://doi.org/10.70284/njirm.v9i2.2313Keywords:
Staphylococcus aureus, Vancomycin, Daptomycin, Minimum Inhibitory ConcentrationAbstract
Background and objectives: Persistent use of Vancomycin in Staphylococcus aureus infections may lead to increase in minimum inhibitory concentration (MIC) levels and thereby failure of treatment. We determined Vancomycin MIC in these strains to identify the need to switch over to other options of treatment like Daptomycin. Methods: All isolates of Staphylococcus aureus from 1st January 2017 to 31st January 2017 were tested with Vitek 2 automated system and MIC of Vancomycin and Daptomycin was determined using E-strips. Patient related information was collected using a structured proforma. Results: For a total of 85 Staphylococcus aureus isolates, the geometric mean for Vancomycin MIC was 0.68 mg/L, the modal MIC was 1 mg/L, the MIC50 and MIC90 values were 0.5 mg/L and 1 mg/L respectively and 55% of isolates had Vancomycin MIC of ≤ 0.5 mg/L. The geometric mean for Daptomycin MIC was 0.34 mg/L, the modal MIC was 0.25 mg/L, the MIC50 and MIC90 were 0.25 mg/L and 0.5 mg/L respectively and 77% of isolates had Daptomycin MIC of ≤ 0.5 mg/L. Interpretation and conclusion: The MIC of Vancomycin has been at the lower side of susceptible range and therefore could be continued as drug of choice in Staphylococcus aureus infections.
References
2. AlÏŒs J, GarcÃa-Cañas A, Garcı´a-Hierro P, Rodrı´guez-Salvane´s F. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage. Journal of Antimicrobial Chemotherapy. 2008; 62:773-775.
3. Chang W, Ma X, Gao P, Lv X, Lu H, Chen F. Vancomycin MIC creep in methicillin-resistant Staphylococcus aureus (MRSA) isolates from 2006 to 2010 in a hospital in China. Indian Journal of Medical Microbiology. 2015; 33 (2):262-266.
4. Wang G, Hindler JF, Ward KW, Bruckner DA. Increased Vancomycin MICs for Staphylococcus aureus Clinical Isolates from a University Hospital during a 5 – Year Period. Journal of Clinical Microbiology. 2006; 44 (11):3883-3886.
5. CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 27th Ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.
6. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S.aureus (MRSA) blood isolates from 2001-05. Journal of Antimicrobial Chemotherapy. 2007; 60:788-794.
7. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Eliopoulos GM. Relationship of MIC and Bactericidal Activity of Efficacy of Vancomycin for Treatment of Methicllin-Resistant Staphylococcus aureus Bacteremia. Journal of Clinical Microbiology. 2004; 42 (6):2398-2402.
8. Humphries RM, Pollett S, Sakoulas G. A Current Perspective on Daptomycin for the Clinical Microbiologist. Clinical Microbiology Reviews. 2013; 26 (4):759-780.
9. Kaur R, Gautam V, Ray P, Singh G, Singhal L, Tiwari R. Daptomycin susceptibility of methicillin resistant Staphylococcus aureus (MRSA). Indian Journal of Medical Research. 2012; 676-677.
10. Moise P, Beringer A, Culshaw D, Bensman JC. Comparative Effectiveness of Vancomycin versus Early Daptomycin for MRSA Bacteremia with Vancomycin MIC > 1 mg/L. Clinical Therapeutics. 2016; 1-15.
11. Dhand A, Sakoulas G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates (‘the MIC Creep’): implications for therapy. F1000 Medicine Reports. 2012; 4 (4):1-11.
12. Diaz R, Afreixo V, Ramalheira E, Rodrigues C, Gago B. Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections – a systematic review and meta-analysis. Clinical Microbiology and Infection. 2018; 24 (2):97-104.
